| Literature DB >> 36177271 |
Aljoharah M Algabbani1, Shahad A Alzahrani1, Salwa M Almomen1, Radwan A Hafiz1.
Abstract
Background: The Saudi Food and Drug Authority (SFDA) requires marketing authorization holders to submit a PIL in both Arabic and English language. However, the readability of imprinted and disseminated Patient information leaflets (PILs) was not assessed extensively in Saudi Arabia. This study aims to assess the readability of PIL of antihypertensive drugs in both Arabic and English languages. Method: This study was a descriptive quantitative analysis conducted in Saudi Arabia in August 2021. PILs of all oral antihypertensive medications in Saudi Arabia were included in the study. The Arabic and English PILs were extracted from the Saudi Drugs Information System (SDI) and pharmaceutical companies' registration documents. The study used Flesch-Kincaid grade level to assess the readability of English and sentence length to assess the Arabic texts. Descriptive analyses were used to assess the readability scores and the mean differences.Entities:
Keywords: ACE, Angiotensin-converting enzyme; ARBs, Angiotensin II receptor blockers; Antihypertensive medications; BBs, Beta-blockers; CCBs, Calcium channel blocker; Consumer health information; EMA, European Medicine Agency; FDA, Food and Drug Administration; FKGL, Flesch-Kincaid grade level; FRE, Flesch Reading Ease; Literacy; MENA, Middle East and North Africa; PAH, Pulmonary Arterial Hypertension; PILs, Patient Information Leaflets; Patient information leaflets; Readability; SDI, Drugs Information System; SFDA, Saudi Food and Drug Authority
Year: 2022 PMID: 36177271 PMCID: PMC9513263 DOI: 10.1016/j.rcsop.2022.100179
Source DB: PubMed Journal: Explor Res Clin Soc Pharm ISSN: 2667-2766
Characteristics of PILs included in the analysis.
| Characteristics | Levels | Medications with English PILs n (%) | Medications with Arabic PILs n (%) | Total without missing | Total with missing |
|---|---|---|---|---|---|
| Type of medication | |||||
| Generic | 152 (70.70) | 131 (68.59) | 152 (70.70) | 175 (70.2) | |
| Brand | 63 (29.30) | 60 (31.41) | 63 (29.30) | 74 (29.7) | |
| Country of the manufacture company | |||||
| Local | 77 (35.81) | 97 (50.79) | 77 (35.81) | 86 (34.5) | |
| Regional | 46 (21.40) | 29 (15.18) | 46 (21.40) | 55 (22.1) | |
| International | 92 (42.79) | 65 (34.03) | 92 (42.79) | 108 (43.4) | |
| Country of marketing company | |||||
| Local | 106 (49.30) | 70 (36.65) | 106 (49.30) | 117 (47) | |
| Regional | 36 (16.74) | 36 (18.85) | 36 (16.74) | 46 (18.5) | |
| International | 73 (33.95) | 85 (44.50) | 73 (33.95) | 86 (34.5) | |
| Therapeutic class | |||||
| ACE | 15 (6.98) | 14 (7.33) | 15 (6.98) | 21 (8.4) | |
| ARBs | 44 (20.47) | 39 (20.42) | 44 (20.47) | 46 (18.5) | |
| Antiadrenergic | 5 (2.33) | 5 (2.62) | 5 (2.33) | 7 (2.8) | |
| Diuretics | 11 (5.12) | 8 (4.19) | 11 (5.12) | 15 (6) | |
| Beta blockers | 27 (12.56) | 24 (12.57) | 27 (12.56) | 30 (12) | |
| Calcium channel blockers | 26 (12.09) | 25 (13.09) | 26 (12.09) | 32 (12.5) | |
| Antihypertensive for PAH | 8 (3.7) | 7 (3.7) | 8 (3.7) | 9 (3.5) | |
| Combinations | 79 (36.74) | 69 (36.13) | 79 (36.74) | 89 (35.7) | |
| Total | 215 | 191 | 215 | 249 | |
| Missing | 58 | 34 | 58 |
Missing data (PILs were not available) were not include it in the final analysis.
Defining country categories:
Local: Saudi Arabia
Regional: all regional Arabic speaking countries
International; all other countries
Means of readability assessment items for English PILs (n = 215).
| Assessment items | Mean | SD | Min | Max |
|---|---|---|---|---|
| Average words per sentence (sentence length) | 9.54 | 2.08 | 4.1 | 15.2 |
| Average number of sentences | 261.72 | 104.09 | 78 | 1066 |
| Average number of words | 2381.50 | 647.41 | 545 | 4348 |
| Average syllables per word | 1.74 | 0.12 | 1.5 | 2.6 |
| Flesch reading ease score | 50.62 | 9.21 | 9.6 | 69.6 |
| Flesh-Kincaid grade level (FKGL) | 8.58 | 1.52 | 5.5 | 14.7 |
Means of readability assessment items for Arabic PILs (n = 191).
| Assessment items | Mean | SD | Min | Max |
|---|---|---|---|---|
| Average words per sentence (sentence length) | 5.5 | 1.31 | 2.45 | 13.88 |
| Average number of sentences | 440.58 | 180.56 | 43 | 1379 |
| Average number of words | 2318.29 | 739.38 | 151 | 5394 |
PILs readability and medications characteristics.
| English PILs (n = 215) | Arabic PILs (n = 191) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Characteristics | Below recommended readability score (<4) | Above recommended readability score (≥4) | p-value | Mean FKGL score (SD) | p-value | Below readability cutoff (<5) | Above readability cutoff (≥5) | p-value | Mean sentence length (SD) | p-value |
| Type of medication | 0.53 | 0.85 | 0.02 | |||||||
| Generic | 17 (11.18) | 135 (88.82) | 8.57 (1.55) | 22 (16.79) | 109 (83.21) | 5.57 (1.36) | 0.3 | |||
| Brand | 9 (14.29) | 54 (85.71) | 8.61(1.44) | 19 (31.67) | 41 (68.33) | 5.36 (1.19) | ||||
| Country of the manufacture company | 0.39 | 0.195 | 0.75 | |||||||
| Local | 7 (9.09) | 70(90.91) | 8.55 (1.49) | 13 (18.57) | 57 (81.43) | 5.62 (1.53) | 0.01 | |||
| Regional | 8 (17.39) | 38 (82.61) | 8.45 (1.77) | 8 (22.22) | 28 (77.78) | 5.50 (1.37) | ||||
| International | 11 (11.96) | 81 (88.04) | 8.68 (1.41) | 20 (23.53) | 65 (76.47) | 5.41 (1.08) | ||||
| Country of marketing company | 0.28 | 0.77 | 0.21 | 0.01 | ||||||
| Local | 10 (9.43) | 96 (90.67) | 8.69 (1.53) | 16 (16.49) | 81 (83.51) | 5.72 (1.45) | ||||
| Regional | 7 (19.44) | 29 (80.56) | 8.18 (1.59) | 7 (24.14) | 22 (75.86) | 5.38 (1.37) | ||||
| International | 9 (12.33) | 64 (87.67) | 8.62 (1.44) | 18 (27.69) | 47 (72.31) | 5.24 (1) | ||||
| Therapeutic class | <0.01 | 0.01 | 0.03 | <0.01 | ||||||
| ACE | 7 (46.67) | 8 (53.33) | 7.6 (1.15) | 4 (28.57) | 10 (71.43) | 4.96 (0.83) | ||||
| ARBs | 11 (25) | 33 (75) | 8.18 (1.54) | 0 | 39 (100) | 6.15 (1.62) | ||||
| Antiadrenergic | 1 (20) | 4 (80) | 7.42 (1.06) | 2 (40) | 3 (60) | 5.79 (1.42) | ||||
| Diuretics | 0 (0) | 11 (100) | 8.7 (1.34) | 2 (25) | 6 (75) | 5.23 (1.14) | ||||
| Beta blockers | 4 (14.81) | 23 (85.19) | 8.37 (1.82) | 8 (33.33) | 16 (66.67) | 5.45 (1.35) | ||||
| Calcium channel blockers | 1 (3.85) | 25 (96.15) | 8.2 (0.94) | 7 (28) | 18 (72) | 5.03 (1.15) | ||||
| Antihypertensive for PAH | 1 (12.5) | 7 (87.50) | 7.55 (0.65) | 2 (28.57) | 5 (71.43) | 5.3 (1.27) | ||||
| Combinations | 1 (1.27) | 78 (98.73) | 9.35 (1.38) | 16 (23.19) | 53 (76.81) | 5.48 (1.15) | ||||
| Total | 26 (12.09) | 189 (87.91) | 8.58 (1.52) | 41 (21.47) | 150 (78.53) | 5.5 (1.31) | ||||
Level 4 = 8th & 9th grade based on the Flesh-Kincaid grade level; as level 3 (7th grade) is the recommended reading level that can be read by 80% of the general population.
Based on sentences length; assessed by the average number of words in a sentence; as 5 words per sentences was the median (cutoff point).
Flesch–Kincaid grade level score interpretations.
| Score | School level | Notes |
|---|---|---|
| 100.00–90.00 | 5th grade (level 1) | Very easy to read. Easily understood by an average 11-year-old student. |
| 90.0–80.0 | 6th grade (level 2) | Easy to read. Conversational English for consumers. |
| 80.0–70.0 | 7th grade (level 3) | Fairly easy to read. |
| 70.0–60.0 | 8th & 9th grade (level 4) | Plain English. Easily understood by 13- to 15-year-old students. |
| 60.0–50.0 | 10th to 12th grade (level 5) | Fairly difficult to read. |
| 50.0–30.0 | College (level 6) | Difficult to read. |
| 30.0–10.0 | College graduate (level 7) | Very difficult to read. Best understood by university graduates. |
| 10.0–0.0 | Professional (level 8) | Extremely difficult to read. Best understood by university graduates. |